CA3174852A1 - Methods and means for modifying hemodynamics in infections - Google Patents

Methods and means for modifying hemodynamics in infections Download PDF

Info

Publication number
CA3174852A1
CA3174852A1 CA3174852A CA3174852A CA3174852A1 CA 3174852 A1 CA3174852 A1 CA 3174852A1 CA 3174852 A CA3174852 A CA 3174852A CA 3174852 A CA3174852 A CA 3174852A CA 3174852 A1 CA3174852 A1 CA 3174852A1
Authority
CA
Canada
Prior art keywords
peptide
aqgv
patients
infection
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174852A
Other languages
English (en)
French (fr)
Inventor
Gert Wensvoort
Eric Claassen
Johan Renes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotempt BV
Original Assignee
Biotempt BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt BV filed Critical Biotempt BV
Publication of CA3174852A1 publication Critical patent/CA3174852A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3174852A 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections Pending CA3174852A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063005999P 2020-04-06 2020-04-06
US63/005,999 2020-04-06
US202063045737P 2020-06-29 2020-06-29
US63/045,737 2020-06-29
US202063085771P 2020-09-30 2020-09-30
US63/085,771 2020-09-30
PCT/NL2021/050223 WO2021206547A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Publications (1)

Publication Number Publication Date
CA3174852A1 true CA3174852A1 (en) 2021-10-14

Family

ID=75581581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174852A Pending CA3174852A1 (en) 2020-04-06 2021-04-06 Methods and means for modifying hemodynamics in infections

Country Status (9)

Country Link
US (1) US20230241155A1 (https=)
EP (1) EP4132556A1 (https=)
JP (2) JP2023521744A (https=)
KR (1) KR20230003495A (https=)
AU (1) AU2021252821A1 (https=)
CA (1) CA3174852A1 (https=)
CO (1) CO2022015018A2 (https=)
MX (1) MX2022012506A (https=)
WO (1) WO2021206547A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
AU2021354766A1 (en) * 2020-09-30 2023-05-11 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
WO2025191033A1 (en) 2024-03-13 2025-09-18 Biotempt B.V. Per-operative treatment of post-operative complications (poc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542791A (en) * 2003-04-08 2008-04-30 Biotempt Bv Compositions for mucosal and oral administration comprising HCG fragments
EP4021481A1 (en) * 2019-08-30 2022-07-06 Biotempt B.V. Q-er peptide
CA3152346A1 (en) * 2019-09-30 2021-04-08 Roelof Peter Pickkers Methods of treatment for modifying hemodynamics

Also Published As

Publication number Publication date
JP2026027378A (ja) 2026-02-18
MX2022012506A (es) 2023-01-16
EP4132556A1 (en) 2023-02-15
WO2021206547A1 (en) 2021-10-14
KR20230003495A (ko) 2023-01-06
JP2023521744A (ja) 2023-05-25
US20230241155A1 (en) 2023-08-03
CO2022015018A2 (es) 2022-10-31
AU2021252821A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
JP2026027378A (ja) 感染症における血行動態を変更する為の方法及び手段
Fraga-Silva et al. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension
CN109010801A (zh) 治疗心力衰竭的组份和方法
AU2006249084A1 (en) Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
US20220370543A1 (en) Methods of treatment for modifying hemodynamics
AU2020337111A1 (en) Q-ER peptide
CN104427993A (zh) 用于治疗由缺氧和低气压造成的肺型高山病的药物组合物
CA2748340A1 (en) .beta.-arrestin effectors and compositions and methods of use thereof
KR102438721B1 (ko) 안지오텐신 전환효소 2를 포함하는 나노디스크 및 안지오텐신 전환효소 2 결핍 질환에 대한 이의 용도
CN112717122A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
US20240016882A1 (en) Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
Sick et al. Activation of CD47 receptors causes histamine secretion from mast cells
US20220323396A1 (en) Compositions and methods for treating viral infection using antiviral cocktails
US20240325496A1 (en) Cxc chemokine agonists and antagonists in covid-19 disease and diagnostic assays
Hamdi et al. The human-COVID-19 tango: connecting the dots
US20240025949A1 (en) Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
CN108553636A (zh) 蛋白c在制备防治肺动脉高压病药物中的应用
WO2016196750A1 (en) Beta-arrestin effectors and compositions and methods of use thereof
WO2021216529A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
Aydt et al. Selectin antagonists and their potential impact for the treatment of inflammatory lung diseaseslate
Moayeri et al. Bacillus anthracis Edema Toxin Inhibits Hypoxic Pulmonary Vasoconstriction 1 via Edema Factor and cAMP Mediated Mechanisms in Isolated Perfused Rat Lungs 2 3 Xizhong Cui1, Jeffrey Wang1, Yan Li1, Zoe G. Couse1, Thomas F. Risoleo1, 4 Mahtab Moayeri2, Stephen H. Leppla2, Daniela Malide3, Zu-Xi Yu3, and Peter Q. Eichacker1 5
WO2021232066A1 (en) Vimentin and fragments or derivatives thereof for coronavirus treatment and prevention
HK40043003A (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
CN102782129A (zh) 药物组合物
Gupta Metalloprotease and endothelin-mediated signaling mechanisms in sepsis and related cardiovascular disorders

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250303

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250403

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250508

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260324